Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Repurchase Up to $120M of Stock

NEW YORK (GenomeWeb News) – Illumina said today that its board of directors has approved the repurchase of up to $120 million of its common stock.
 
"Given the underlying strength of Illumina's business and the recent turbulence in the equity markets, we think our current stock price is undervalued,” said Illumina President and CEO Jay Flatley. “Therefore, we believe the stock buy-back program is in the best interests of our stockholders.”
 
Earlier this week, the firm posted third-quarter revenue growth of 54 percent to $150.3 million.
 
Illumina said that the purchases would be made on the open market or through privately negotiated transactions. It will fund the purchases with existing cash balances, it said.
 

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.